Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at Oxford University have been awarded a £6 million grant for their cutting-edge research programme on finding drug targets for Parkinson's Disease.

This new funding builds on an initial £5M investment from Parkinson’s UK to researchers at the Oxford Parkinson’s Disease Centre (OPDC) in 2010.

One in 500 people in Oxfordshire have Parkinson's – a neurological condition which can leave people struggling to walk, speak and sleep, and which has no cure.

By 2020 the multidisciplinary team at Oxford hopes to use the £6 million to find new drugs to slow, or even stop Parkinson's, using a 'brain cell bank' they have developed to identify promising new drug targets. They also want to improve how to diagnose and monitor Parkinson's using new technology, such as smartphone apps.

In the last five years, the team has developed one of the largest studies of people living with Parkinson's anywhere in the world, leading to progress in understanding why brain cells die and in detecting early changes in patients before full symptoms occur. Working with Thames Valley patients the team have created a tool to detect early stage Parkinson's with 85% accuracy using brain imaging.

Professor Richard-Wade Martins, lead researcher at the OPDC, said of receiving the funding: 'In the last five years we've made remarkable progress. We've built a study integrating work in the clinic and the laboratory like nowhere else in the world. Alongside this, our program to change cells from patients' skin into brain cells using cutting-edge stem cell technology has allowed us to gain completely new insights about Parkinson's and how it develops.

We’re delighted the new funding from Parkinson’s UK will secure the future of this and other vital projects.'

Read more

                   

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Professor Dame Frances Ashcroft to receive Vanderbilt Prize in Biomedical Science

The Vanderbilt Prize in Biomedical Science recognises women scientists with a stellar record of research accomplishments who also have made significant contributions to mentoring other women in science.

Annie Park to advance our understanding of how the brain encodes reward with new Wellcome Trust Award

Congratulations are in order for Postdoctoral Fellow Dr Annie Park who has been awarded a prestigious Wellcome Early-Career Award.

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.